Phase I Trial of PX-478
NCT00522652
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Lymphoma
Interventions
DRUG:
PX-478
Sponsor
Cascadian Therapeutics Inc.